Peptide Therapy: Understanding the Regulatory Picture First

Before asking what a peptide might do, there is a prior question that most marketing skips entirely: whether any pharmacy may lawfully make it at all. That answer changes, and it has changed recently for several widely discussed compounds.

The peptide market runs on a specific rhetorical move: skipping straight to what a compound supposedly does, so that the question of whether it can legally be dispensed never comes up. Understanding the regulatory structure removes most of the ambiguity, and it is the single most useful thing a patient can learn about this field. It is also the thing that separates a clinical service from an online storefront.

What a peptide is

Peptides are short chains of amino acids linked by peptide bonds. Proteins are the same chemistry at greater length; the boundary between the two is a matter of convention rather than a hard line, and FDA has used a specific amino-acid count in defining which molecules are regulated as drugs rather than as biologics. That definitional detail is not trivia — it determines which regulatory pathway a molecule travels down.

The body makes enormous numbers of peptides, and they do many things: hormonal signalling, immune modulation, metabolic regulation. Some peptide medicines have been developed, tested and approved, and they are unremarkable parts of medicine. Insulin is a peptide. So are several widely used hormone analogues. Approved peptide drugs exist and work.

What follows is not about those. It is about the much larger set of peptides discussed on forums, in podcasts and by clinics — compounds that have not been through approval for the uses being described.

What FDA approval actually involves

An approved drug has been through preclinical work, then human trials in phases: initial safety and dose-finding in small numbers, then studies of effectiveness in the target condition, then larger trials establishing efficacy and detecting less common adverse effects. The sponsor submits the complete dataset. FDA reviews it, including the manufacturing process, and either approves the drug for a specified indication at a specified dose with specified labelling, or does not.

Approval is narrow. A drug is approved for particular uses, in particular populations, at particular doses. And it carries obligations afterwards — adverse event reporting, manufacturing inspection, labelling requirements.

When something is described as "not FDA-approved", what that means for a patient is concrete. No regulator has assessed whether it works for the stated purpose. No regulator has assessed its safety at the doses being used. There is no approved labelling telling anyone the correct dose, contraindications, interactions or known adverse effects. There is no manufacturing standard tied to that use. And there is no post-market surveillance system collecting harms.

Compounding: 503A and 503B

Compounding is the preparation of a medication for a patient by combining or altering ingredients. It has a legitimate, long-standing place in medicine — a patient who needs a dose that is not manufactured, or who cannot tolerate a dye or preservative in the commercial product, or who needs a liquid instead of a tablet.

Two sections of federal law govern it, and the difference is worth understanding.

Section 503A

Traditional compounding pharmacies. They prepare medications for individually identified patients pursuant to a valid prescription. They are primarily regulated by state boards of pharmacy. They are exempt from certain federal requirements — including FDA approval of the product and full current good manufacturing practice requirements — provided they meet the conditions in the statute. They are not permitted to compound at scale for general distribution without prescriptions.

Section 503B

Outsourcing facilities. Created in the wake of a fatal contamination outbreak traced to a compounder, this category allows larger-scale production, including without patient-specific prescriptions, in exchange for stricter obligations. Outsourcing facilities register with FDA, must comply with current good manufacturing practice requirements, are subject to FDA inspection, and must report adverse events.

What both share: compounded preparations are not FDA-approved. Compounding is an exemption from approval, not an alternative form of it. A 503B facility making a compound under CGMP has better manufacturing controls than a small 503A pharmacy, but the product still has not been evaluated by FDA for safety and effectiveness. The same misunderstanding causes problems in the weight-loss market, which we cover in our article on compounded GLP-1s.

Bulk drug substances, and why availability keeps moving

Here is the mechanism that governs most peptide availability.

To compound from a raw active ingredient — a bulk drug substance — rather than from an approved finished drug, the substance generally has to satisfy one of a limited set of conditions. It may be the subject of an applicable USP or NF monograph. It may be a component of an FDA-approved drug. Or it may appear on a list FDA develops of bulk substances that may be used in compounding. There are parallel but distinct lists for 503A and 503B.

Substances are nominated for those lists, and FDA evaluates them. During evaluation, FDA has sorted nominated substances into categories. Broadly, some substances may be used while evaluation continues; others are placed in a category FDA has identified as raising significant safety risks, and those are not appropriate for compounding. Several widely discussed research peptides sit in that second group. FDA has publicly flagged concerns about certain peptide substances including questions about immunogenicity, peptide-related impurities, and insufficient safety data at the doses proposed.

The consequence is the pattern patients actually experience. A compound is discussed everywhere online. Clinics offer it. Then it becomes unavailable, or clinics quietly stop mentioning it, and no explanation is given. The explanation is usually regulatory, not commercial.

These lists are living documents. FDA continues to evaluate nominations, categories change, and enforcement priorities shift. Nothing in this article should be treated as a current snapshot — check FDA's own published lists, and verify anything time-sensitive directly with the regulator before relying on it.

The unregulated tier below all of this

Everything above concerns products dispensed through licensed pharmacies against prescriptions. There is a separate market entirely: vials sold online labelled "for research purposes only, not for human consumption".

That label is not a formality. It places the product outside the drug regulatory framework altogether — nothing has been verified about identity, concentration, purity or sterility, and there is no pharmacy, no prescriber and no recourse. We cover this in detail in the research peptide grey market, and it is the most dangerous corner of the subject.

What this means when you are deciding

Ask directly whether what is being proposed is FDA-approved, and for what indication. If it is not, ask what its regulatory basis is. Ask which pharmacy prepares it, whether that pharmacy is a 503A pharmacy or a 503B outsourcing facility, and in which state it is licensed. Ask what evidence exists in humans, and ask for the citation rather than the summary. Ask what happens if you have an adverse reaction and who is responsible for managing it.

Expect some honest uncertainty in the answers. Regulatory status genuinely does change, and a provider saying "that was available last year and is not now, here is why" is being straight with you. What should concern you is confidence without substance — a clinic that describes a compound as safe and effective, dismisses the regulatory question as red tape, or cannot name the pharmacy.

The wider question of how to tell a real remote practice from a storefront with a doctor's name on it is covered in what telehealth is actually good for. If you want to understand how we approach this area, our peptide therapy page sets out the framework — including the point that no consultation results in a guaranteed prescription, and that a great many appropriate answers do not involve a peptide at all.